Dr. Brawer on Predicting Radical Prostatectomy Outcomes

Michael Brawer, MD
Published: Tuesday, Jul 22, 2014

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

This study looked to answer the question as to whether grade is as important of a predictive tool as it has been in the past. Patients with gleason score (GS) <7 were analyzed. Their initial GS were compared with their score on radical prostatectomy.

The results of this study indicate that the risk of biochemical recurrence is indistinguishable in men with GS <7 who have pathologic GS 3+4 or 4+3. The Prolaris test does provide stratification of this risk.

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

This study looked to answer the question as to whether grade is as important of a predictive tool as it has been in the past. Patients with gleason score (GS) <7 were analyzed. Their initial GS were compared with their score on radical prostatectomy.

The results of this study indicate that the risk of biochemical recurrence is indistinguishable in men with GS <7 who have pathologic GS 3+4 or 4+3. The Prolaris test does provide stratification of this risk.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x